CuraSen Therapeutics, Inc.
CuraSen Therapeutics develops orphan drugs targeting neurodegenerative diseases by utilizing advanced pharmacological approaches to enhance neuroprotection and promote neuronal health. The company focuses on addressing the unmet medical needs of patients suffering from conditions like Alzheimer's and Parkinson's, where current treatment options are limited.
- Biotechnology
Funding
Raised to date
$5.8MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Kathleen Glaub
Chief Executive Officer
Product
Problem
Neurodegenerative diseases like Alzheimer's and Parkinson's have limited effective treatment options, resulting in significant unmet medical needs for patients suffering from these conditions. Current therapies often fail to adequately address the underlying neuronal damage and loss of function associated with disease progression.
Solution
CuraSen Therapeutics is developing a portfolio of therapeutics designed to enhance neuroprotection and promote neuronal health in patients with neurodegenerative diseases. Their approach focuses on utilizing advanced pharmacological strategies to target key mechanisms involved in neuronal survival and function. By addressing the underlying causes of neurodegeneration, CuraSen aims to develop disease-modifying therapies that can slow or halt disease progression and improve patient outcomes.
Target Audience
The primary target audience includes patients suffering from neurodegenerative diseases such as Alzheimer's and Parkinson's, as well as the healthcare professionals who treat them.
Features
- Development of novel pharmacological agents targeting neurodegenerative pathways.
- Focus on enhancing neuroprotection to prevent neuronal damage and loss.
- Promotion of neuronal health to improve function and resilience.
- Pipeline of orphan drugs designed to address unmet medical needs in rare neurodegenerative diseases.